ONCOS-102 (Oncos therapeutics) with Δ24 deletion within Rb-binding E1A gene, insertion of GM-CSF-encoding gene and replacement of serotype 3 AV knob protein was also granted by FDA as an orphan drug against ovarian cancer, glioma, and malignant mesothelioma [42,43,44]. Here, CSF2 is linked to ovarian carcinoma.